Literature DB >> 1689452

Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxyuridine-5'-triphosphate.

Z Hao1, D A Cooney, D Farquhar, C F Perno, K Zhang, R Masood, Y Wilson, N R Hartman, J Balzarini, D G Johns.   

Abstract

2',3'-Dideoxyuridine (ddUrd) exhibits poor if any anti-human immunodeficiency virus (HIV) activity in ATH8 and MT-4 cells. This is in agreement with the failure of ddUrd to be efficiently anabolized intracellularly to its 5'-triphosphate metabolite. However, 2',3'-dideoxyuridine-5'-triphosphate (ddUTP) proved to be a potent and selective inhibitor of the reverse transcriptase of HIV (Ki, 0.05 microM) and avian myeloblastosis virus (Ki, 1.0 microM). Bacterial DNA polymerase I, mammalian DNA polymerase alpha, terminal deoxyribonucleotidyl transferase, and Moloney murine leukemia virus reverse transcriptase were resistant to ddUTP. ddUTP is incorporated into the growing DNA chain principally at dTTP sites and inhibits further elongation. The potential of ddUTP as an anti-HIV therapeutic agent merits further investigation. However, to achieve this goal, it will be necessary to resort to techniques capable of delivering preformed phosphorylated ddUrd to the susceptible cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689452

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

1.  Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives.

Authors:  J Balzarini; A Karlsson; S Aquaro; C F Perno; D Cahard; L Naesens; E De Clercq; C McGuigan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 2.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

Review 3.  Prodrugs of pyrophosphates and bisphosphonates: disguising phosphorus oxyanions.

Authors:  Emma S Rudge; Alex H Y Chan; Finian J Leeper
Journal:  RSC Med Chem       Date:  2022-03-01

Review 4.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

5.  3'-Azido-3'-deoxythymidine-induced reduction in the ability of uninfected CD4-expressing cells to participate in syncytium formation.

Authors:  R W Buckheit; J Germany-Decker; K Qualls-Goodwin; B J Bowdon; W M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

6.  2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.

Authors:  J Balzarini; M J Pérez-Pérez; A San-Félix; D Schols; C F Perno; A M Vandamme; M J Camarasa; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

Review 7.  Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection.

Authors:  K Peter; J G Gambertoglio
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

8.  Molecular structures of two new anti-HIV nucleoside analogs: 9-(2,3-dideoxy-2-fluoro-beta-D-threo-pentofuranosyl)adenine and 9-(2,3-dideoxy-2-fluoro-beta-D-threo-pentofuranosyl)hypoxanthine.

Authors:  Y C Liaw; Y G Gao; V E Marquez; A H Wang
Journal:  Nucleic Acids Res       Date:  1992-02-11       Impact factor: 16.971

Review 9.  The ProTide Prodrug Technology: From the Concept to the Clinic.

Authors:  Youcef Mehellou; Hardeep S Rattan; Jan Balzarini
Journal:  J Med Chem       Date:  2017-08-24       Impact factor: 7.446

10.  Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection.

Authors:  Jiapeng Li; Shuhan Liu; Jian Shi; Hao-Jie Zhu
Journal:  Pharmaceutics       Date:  2021-10-11       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.